Background: Semaglutide is a Glucagon-like peptide-1 receptor agonist (GLP-1RA) used in the treatment of type 2 diabetes mellitus (T2DM) and weight management. While its clinical benefits are well established, concerns have emerged over off-label use, underreporting of adverse drug reactions (ADRs), and prescribing disparities. Aims: To examine real-world prescribing pattern treatment efficacy and ADRs associated with semaglutide in a socioeconomically deprived United Kingdom (UK) locality, and to compare these with national data. Methods: A retrospective service evaluation was conducted using anonymised data from 1403 patients across 42 GP practices under a data share agreement across a place-based group of practices in the West Midlands. National prescribing data were obtained from OpenPrescribing, and ADR data from the Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card Scheme (01/2020–12/2024). Analyses included demographic trends, treatment efficacy (HbA1c and weight), and socioeconomic comparisons using the Socioeconomic Index for Small Areas (SEISA) deciles. Findings: Semaglutide prescribing in the GP surgeries studied peaked in 2022 and declined thereafter, mirroring national trends. Prescribing of semaglutide mirrored the ethnic make-up of the region studied with a notable exception of White British. Mean HbA1c fell by 10.8 mmol/mol and weight by 4.8%. ADR incidence in the population studied (1.85%) exceeded national reporting rates (0.20%). Prescribing was highest in practices serving the most deprived communities. Conclusions: Semaglutide is effective in reducing HbA1c and weight in real-world settings. However, ADRs remain underreported. Socioeconomic deprivation was strongly associated with higher prescribing rates. Greater attention to equitable access and pharmacovigilance is warranted.
Reducing low-density lipoprotein cholesterol levels lowers the risk of atherosclerotic cardiovascular disease. With the current and future portfolios of emerging lipid-lowering therapies included in various national and international guidelines, the objectives of this study were (i) to investigate the perceptions of UK prescribers’, including doctors, pharmacists, and nurses, on current lipid management for cardiovascular diseases and prescriptions of novel lipid-lowering therapies, and (ii) to explore the challenges and facilitating factors of prescribing novel lipid-lowering therapies through qualitative interviews. Qualitative semi-structured interviews with twelve medical and non-medical prescribers were conducted, around 20–30 min in length. The interviews were audio-recorded and transcribed on an online platform. A thematic analysis was deployed. Four major themes emerged from the analysis: (1) prescribing barriers; (2) prescribing enablers; (3) inter-profession variability; and (4) health literacy. These themes highlighted the contrast between the need for optimal shared decision making and the various constraints in practice. Participants expressed their inexperience with novel lipid-lowering therapies and acknowledged the requirement and importance of these agents for primary cardiovascular disease prevention. Participants recognised confidence and competence as key drivers for prescribing therapies and welcomed further education and training to enhance their skillset. Patients’ misconceptions towards current lipid-lowering therapies contributed to their refusal of newer agents, highlighting a requirement to improve patient education. Targeting communities through awareness campaigns was identified as a viable solution.
Background: Cardiovascular disease is a leading cause of mortality in England, with South Asians estimated to have a higher risk of CVD development compared to the general population. Harmful drinking is a key risk factor for cardiovascular disease, but little is known about drinking behaviours among South Asians, especially those aged 18–25. Objectives: The objectives of this study were (i) to investigate the knowledge of the cardiovascular effects of harmful drinking among young South Asians aged 18–25, and (ii) to explore the perceptions of young South Asians towards the role of the pharmacist in supporting individuals with alcohol-related harm. Methods: Qualitative, in depth, face-to-face, semi-structured interviews were conducted with ten young South Asians, around 30 min in length. The interviews were audio recorded, transcribed verbatim and then thematically analysed. Results: Four superordinate themes emerged: (1) Culture Clash; (2) The Great Escape; (3) Cardiovascular Confusion; and (4) The Ambiguous Pharmacist. These themes highlighted a dichotomy between the drinking behaviours among different South Asian communities, a lack of knowledge regarding the cardiovascular consequences of harmful drinking and mixed views regarding pharmacists’ role in supporting dependence. Participants acknowledged the prevalence of poor cardiovascular health among British South Asians, citing various types of dysfunction and possible causes; however, the effect of drinking specifically was not understood. Most participants would refer a young person struggling with dependence to a pharmacist and would be receptive to discussing drinking with one. However, few commented on any role outside of signposting to other services or healthcare providers. Conclusions: Greater cardiovascular health promotion is needed among South Asians, with an emphasis on the link between excess alcohol consumption and cardiovascular dysfunction. Furthermore, pharmacists must do more to promote greater awareness of the different ways in which alcohol dependence can be supported within the community to encourage young people seeking harm reduction to utilise those services as needed.
Background: Gestational diabetes mellitus and mental disorders may co-exist during pregnancy. Mental disorders may be present prior to pregnancy or emerge during the gestational period, and both conditions have been independently associated with adverse maternal and neonatal outcomes. However, the extent and nature of their interrelationship remain unclear, particularly in observational research. Therefore, this review aimed to address the following questions: whether and how the two conditions are related, what support mechanisms are available to patients, and how the link between gestational diabetes mellitus varies across different mental disorders. Methods: A systematic review of seven databases (PubMed, Embase, Medline, CINAHL, Scopus, PsycINFO, and Web of Science) was conducted to identify observational studies published between January 2019 and October 2024 that examined gestational diabetes mellitus and mental disorders in pregnancy. The protocol was published in PROSPERO (CRD42024608711). The quality of the included studies was assessed using the National Institute of Health (NIH) tool for observational studies. Findings were categorised into the following themes: the interconnection between gestational diabetes mellitus and mental disorders; support strategies for gestational diabetes mellitus and mental disorders; the link between gestational diabetes mellitus and the variability of mental disorders; and factors associated with maternal and neonatal outcomes. Results: Eleven studies met the inclusion criteria. Findings indicate an association between gestational diabetes mellitus and various mental disorders, particularly depression and anxiety; however, the directionality of this association remains uncertain. Socioeconomic status, ethnicity, and trauma history emerged as potential modifiers. Non-pharmacological interventions were preferred for both conditions, though pharmacological treatments were sometimes necessary. Conclusions: There is growing evidence of a complex interaction between gestational diabetes mellitus and mental disorders during pregnancy, though causality remains unconfirmed. Clinicians also should prioritise lifestyle-based interventions, monitor pharmacotherapy risks, and provide integrated care for affected patients. Further longitudinal studies are needed to elucidate the directionality and mechanisms underpinning this association. Clinical trial number: Not applicable.